Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0774 • ACR Convergence 2020
Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Chronic Antigen-stimulation and an Altered T Cell Receptor Repertoire
Judith Ashouri-Sinha¹, Elizabeth McCarthy¹, Steven Yu², Chun Jimmie Ye¹ and Arthur Weiss¹, ¹UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, ²UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francsico, CA
Background/Purpose: T cells can either be activated through their T cell receptor (TCR) in an antigen-specific manner, or in response to cytokines. Identification of antigen-reactive…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 0807 • ACR Convergence 2020
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Akhil Sood¹, Soham Al Snih¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid…
Abstract Number: 0824 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Ying Shan¹, Page Moore¹, Lin Guo¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
Abstract Number: 0967 • ACR Convergence 2020
Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Marc Nuzzo³, Stacey Duemmel³, Benjamin Korman¹ and Christopher Ritchlin¹, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, West Henrietta, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester
Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein noted to be expressed on many cells including T lymphocytes, stem cells, osteoblasts and fibroblasts.…
Abstract Number: 1005 • ACR Convergence 2020
Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study
Ajinkya Pawar¹, Rishi Desai¹, Mengdong He¹, Lily Bessette¹ and Seoyoung Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) increases risk of osteoporosis and fractures. However, limited head-to-head comparative data exists on the risk of non-vertebral osteoporotic fractures (NVFs) among…
Abstract Number: 1130 • ACR Convergence 2020
Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research
Abhishikta Dey¹, Marita Cross², Tom Lynch³, Carlos El-Haddad⁴ and Lyn March⁵, ¹NSW Rheumatology Advanced Trainee, Sydney, New South Wales, Australia, ²Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ³A3BC, Sydney, New South Wales, Australia, ⁴Liverpool Hospital, Sydney, Australia, ⁵Institute of Bone and Joint Research, University of Sydney, Sydney, New South Wales, Australia
Background/Purpose: The causes of arthritis and autoimmune conditions remain unknown. A complex interplay of genetic and environmental factors is thought to underlie these diseases. Prospective…
Abstract Number: 1192 • ACR Convergence 2020
Subclinical Coronary Calcification Associated with Long-term Cardiovascular Outcomes in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: Large, multicenter studies established the strong prognostic value of coronary artery calcium (CAC) scoring in asymptomatic individuals. Increasing CAC score is an independent predictor…
Abstract Number: 1208 • ACR Convergence 2020
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, ChanKyoung Hwang⁹ and DaeSeok Choi⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: Novel subcutaneous infliximab (CT-P13 SC) was developed to augment the flexibility in the therapeutic use of infliximab and non-inferiority (NI) of CT-P13 SC versus…
Abstract Number: 1225 • ACR Convergence 2020
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy
Yoshinobu Koyama¹, Yoshiharu Sato², Hiroshi Iijima², Moe Sakamoto³ and Toshie Higuchi³, ¹Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Division of Rheumatology, Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan
Background/Purpose: Inhibition of IL-6 signaling is one of the most established strategies for RA treatment. Tocilizumab (TCZ) is the pioneer which blocks IL-6 signaling by…
Abstract Number: 1339 • ACR Convergence 2020
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Rebecca Haberman¹, Rochelle Castillo¹, Alan Chen², Di Yan¹, Deborah Ramirez², Vaish Sekar², Robert Lesser², Gary Solomon², Andrea Neimann², Rebecca Blank¹, Peter Izmirly³, Dan Webster⁴, Alexis Ogdie⁵, Andrea Troxel², Samrachana Adhikari² and Jose Scher¹, ¹NYU School of Medicine, New York City, ²NYU Langone Health, New York City, ³New York University, New York, NY, ⁴Sage Bionetworks, Seattle, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…
Abstract Number: 1471 • ACR Convergence 2020
Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study
Jill Hahn¹, May Choi², Susan Malspeis³, Emma Stevens⁴, Elizabeth Karlson⁴, Kazuki Yoshida⁵, Laura Kubzansky⁶, Jeffrey Sparks⁷ and Karen Costenbader⁸, ¹Brigham and Womens' Hospital, Newton, MA, ²Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Many potentially modifiable biobehavioral factors have been associated with the risk of developing rheumatoid arthritis (RA), but the benefit of adopting an overall healthy…
Abstract Number: 1549 • ACR Convergence 2020
Joint Damage and Malalignment Determine Articular Tenderness More Than Inflammation in Rheumatoid Arthritis, Psoriatic Arthritis or Osteoarthritis in Established Disease
Mihaela Popescu¹, Victoria Schimpl², Gabriela Supp³, Martina Durechova³, Paul Studenic³, Michael Zauner³, Josef Smolen³, Daniel Aletaha⁴, Peter Mandl³ and Irina Gessl³, ¹Hôpital Maisonneuve-Rosemont, Montreal, Canada, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria
Background/Purpose: To determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA) or psoriatic…
Abstract Number: 1702 • ACR Convergence 2020
RA-Related Knowledge and Skills of Rheumatology Fellows Among 20 US Academic Institutions
Sandeep Agarwal¹, Rebecca Manno², Kristina Fajardo³, Laura Simone³, Jeff Carter³ and Tamar Sapir³, ¹Baylor College of Medicine, Houston, TX, ²Johns Hopkins University School of Medicine, St. Thomas, Virgin Islands, U.S., U.S. Virgin Islands, ³PRIME Education, LLC, Fort Lauderdale, FL
Background/Purpose: As the rheumatology workforce experiences an alarming shortage, it is critical that rheumatology fellows receive advanced training experiences to reinforce their commitment to rheumatology…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].